Vivos Therapeutics, Inc. (Vivos), a medical technology company, announced the filing of its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) on October 7, 2024. The proxy statement pertains to the upcoming 2024 Annual Meeting of Stockholders scheduled for November 26, 2024, at 10:00 a.m. Mountain Time. The meeting will be conducted entirely online via live webcast. Stockholders are invited to attend, vote, and submit questions during the virtual meeting. The company emphasizes the importance of stockholder participation, urging them to vote promptly by internet, telephone, or mail. The proxy statement includes proposals for the election of directors, approval of the company's proposed 2024 Omnibus Equity Incentive Plan, and ratification of Moss Adams LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The board recommends voting in favor of all proposals. The proxy statement and annual report are available on the company's investor relations website, and printed materials will be mailed to stockholders of record as of October 4, 2024, around October 15, 2024.

Vivos Therapeutics, Inc. (Vivos), a medical technology company, announced the filing of its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) on October 7, 2024. The proxy statement pertains to the upcoming 2024 Annual Meeting of Stockholders scheduled for November 26, 2024, at 10:00 a.m. Mountain Time. The meeting will be conducted entirely online via live webcast. Stockholders are invited to attend, vote, and submit questions during the virtual meeting. The company emphasizes the importance of stockholder participation, urging them to vote promptly by internet, telephone, or mail. The proxy statement includes proposals for the election of directors, approval of the company's proposed 2024 Omnibus Equity Incentive Plan, and ratification of Moss Adams LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The board recommends voting in favor of all proposals. The proxy statement and annual report are available on the company's investor relations website, and printed materials will be mailed to stockholders of record as of October 4, 2024, around October 15, 2024.